Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Next Previous
Trial Profile

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Droxidopa (Primary) ; Midodrine (Primary)
  • Indications Autonomic-nervous-system-disorders; Multiple system atrophy; Orthostatic hypotension; Parkinson's disease
  • Focus Therapeutic Use

Most Recent Events

  • 14 Oct 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
  • 14 Oct 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
  • 12 Dec 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top